FUSION PROTEINS AND METHODS THEREOF

1 .- 31 . (canceled)

32 . A method for treating a FGFR1-TACC1 fusion associated cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of JNJ-42756493, wherein the subject has a FGFR1-TACC3 fusion associated cancer, wherein the FGFR1-TACC1 fusion comprises a tyrosine kinase domain of FGFR1 fused to the TACC domain of transforming acidic coiled-coil-containing (TACC)-1.

33 . The method of claim 32 , wherein the subject has FGFR1-TACC1 fusion associated epithelial cancer, glioma, glioblastoma multiforme, breast cancer, lung cancer, prostate cancer, bladder carcinoma, squamous lung carcinoma, head and neck carcinoma or colorectal carcinoma.

34 . The method of claim 32 , wherein the subject has FGFR1-TACC1 fusion associated epithelial cancer, glioblastoma multiforme, or glioma.

35 . The method of claim 34 , wherein the glioma is a grade II or III glioma.

36 . The method of claim 34 , wherein the subject does not have mutations in IDH1 or IDH2 genes.

37 . The method of claim 34 , wherein the subject does not have a gene amplification in EGFR.

38 . The method of claim 34 , wherein the subject does not express EGFRγIII transcript variant.

39 . The method of claim 34 , wherein the subject has a gene amplification of CDK4, MDM2, or both.

40 . The method of claim 32 , wherein the FGFR1-TACC1 fusion comprises SEQ ID NO: 88.

41 . The method of claim 32 , wherein the FGFR1-TACC1 fusion comprises SEQ ID NO: 150.

42 . A method for treating a FGFR1-TACC1-fusion associated cancer in a subject in need thereof, the method comprising:

a. obtaining a biological sample from the subject;

b. detecting whether or not the subject has a FGFR1-TACC1 fusion, wherein the FGFR1-TACC1 fusion comprises a tyrosine kinase domain of FGFR1 fused to the TACC domain of transforming acidic coiled-coil-containing (TACC)-1; and

c. administering to the subject an effective amount of JNJ-42756493 if in the subject has a FGFR1-TACC1 fusion protein.